on Thursday warned of a steeper earnings decline on a slump in demand for materials used to produce pharmaceuticals and semiconductors, as its high-tech niche markets get drawn into a wider downturn.
Earnings before interest, taxes, depreciation and amortisation , before one-offs, would fall between 3% and 9%, when adjusted for currency swings, the diversified company said.It had previously forecast 2023 adjusted EBITDA to slip between 0% and 5%, with an additional negative foreign exchange effect of 2% to 5%.
The Life Science unit, in turn, was hit by a slump in COVID-19-related demand for lab gear and by drugmakers running down excess inventory levels rather than ordering Merck's materials.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: